JP2015513083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513083A5 JP2015513083A5 JP2014558737A JP2014558737A JP2015513083A5 JP 2015513083 A5 JP2015513083 A5 JP 2015513083A5 JP 2014558737 A JP2014558737 A JP 2014558737A JP 2014558737 A JP2014558737 A JP 2014558737A JP 2015513083 A5 JP2015513083 A5 JP 2015513083A5
- Authority
- JP
- Japan
- Prior art keywords
- psma
- agent
- imaging
- adenocarcinoma
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261602900P | 2012-02-24 | 2012-02-24 | |
| US61/602,900 | 2012-02-24 | ||
| PCT/US2013/000045 WO2013126147A2 (en) | 2012-02-24 | 2013-02-22 | Elevated psma identifies lethal prostate cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019050913A Division JP2019144254A (ja) | 2012-02-24 | 2019-03-19 | Ｐｓｍａ上昇により致死性前立腺癌が同定される |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015513083A JP2015513083A (ja) | 2015-04-30 |
| JP2015513083A5 true JP2015513083A5 (enExample) | 2016-03-31 |
| JP6501524B2 JP6501524B2 (ja) | 2019-04-17 |
Family
ID=49003541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558737A Expired - Fee Related JP6501524B2 (ja) | 2012-02-24 | 2013-02-22 | Ｐｓｍａ上昇により致死性前立腺癌が同定される |
| JP2019050913A Pending JP2019144254A (ja) | 2012-02-24 | 2019-03-19 | Ｐｓｍａ上昇により致死性前立腺癌が同定される |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019050913A Pending JP2019144254A (ja) | 2012-02-24 | 2019-03-19 | Ｐｓｍａ上昇により致死性前立腺癌が同定される |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130225541A1 (enExample) |
| EP (2) | EP3064945A1 (enExample) |
| JP (2) | JP6501524B2 (enExample) |
| CA (1) | CA2865282A1 (enExample) |
| HK (1) | HK1205788A1 (enExample) |
| WO (1) | WO2013126147A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1202256A1 (en) * | 2012-02-28 | 2015-09-25 | Cornell University | Psma as a biomarker for androgen activity in prostate cancer |
| US10340046B2 (en) | 2016-10-27 | 2019-07-02 | Progenics Pharmaceuticals, Inc. | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications |
| CA3050085A1 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| CA3056261A1 (en) | 2017-04-07 | 2018-10-11 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| US12602772B2 (en) | 2018-01-08 | 2026-04-14 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
| CN113272859B (zh) | 2019-01-07 | 2025-04-04 | 西尼诊断公司 | 用于平台中立性全身图像分段的系统及方法 |
| TWI872062B (zh) | 2019-04-24 | 2025-02-11 | 美商普吉尼製藥公司 | 用於偵測轉移之骨掃描影像之自動及互動式分析系統、裝置及方法 |
| US12417533B2 (en) | 2019-09-27 | 2025-09-16 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US11900597B2 (en) | 2019-09-27 | 2024-02-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| IL320607A (en) | 2020-03-26 | 2025-07-01 | Ramirez Fort Marigdalia Kaleth | Ultraviolet radiation treatments |
| US11721428B2 (en) | 2020-07-06 | 2023-08-08 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
| AU2022361659A1 (en) | 2021-10-08 | 2024-03-21 | Exini Diagnostics Ab | Systems and methods for automated identification and classification of lesions in local lymph and distant metastases |
| CN119791845B (zh) * | 2025-01-03 | 2026-05-08 | 北京大学第一医院(北京大学第一临床医学院) | 一种降低前列腺根治性切除术后切缘阳性的治疗设备 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002098885A1 (en) * | 2001-02-07 | 2002-12-12 | Beth Israel Deaconess Medical Center | Modified psma ligands and uses related thereto |
| JP4619651B2 (ja) * | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
| ATE408712T1 (de) * | 2003-01-10 | 2008-10-15 | Millennium Pharm Inc | Verfahren zur bestimmung des wiederauftretens von prostata krebs |
| WO2005021709A2 (en) * | 2003-05-29 | 2005-03-10 | Diadexus, Inc. | Cln101 antibodies |
| RU2450832C2 (ru) * | 2006-10-25 | 2012-05-20 | Конинклейке Филипс Электроникс Н.В. | Контрастные вещества для детекции рака предстательной железы |
| WO2009046294A2 (en) * | 2007-10-03 | 2009-04-09 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
| EP2281004A4 (en) * | 2008-04-14 | 2012-02-15 | Proscan Rx Pharma Inc | PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS |
| WO2010065940A1 (en) * | 2008-12-04 | 2010-06-10 | The Regents Of The University Of California | Materials and methods for determining diagnosis and prognosis of prostate cancer |
| EP3495000A1 (en) * | 2009-02-17 | 2019-06-12 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| US8772226B2 (en) * | 2009-03-17 | 2014-07-08 | The Johns Hopkins University | Methods and compositions for the detection of cancer |
-
2013
- 2013-02-22 US US13/773,857 patent/US20130225541A1/en not_active Abandoned
- 2013-02-22 CA CA2865282A patent/CA2865282A1/en not_active Abandoned
- 2013-02-22 EP EP16166503.9A patent/EP3064945A1/en not_active Withdrawn
- 2013-02-22 JP JP2014558737A patent/JP6501524B2/ja not_active Expired - Fee Related
- 2013-02-22 HK HK15106199.9A patent/HK1205788A1/xx unknown
- 2013-02-22 EP EP13752566.3A patent/EP2817629A4/en not_active Withdrawn
- 2013-02-22 WO PCT/US2013/000045 patent/WO2013126147A2/en not_active Ceased
-
2017
- 2017-05-15 US US15/595,533 patent/US20180088120A1/en not_active Abandoned
-
2019
- 2019-03-19 JP JP2019050913A patent/JP2019144254A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alam et al. | Emerging intraoperative imaging modalities to improve surgical precision | |
| Giesel et al. | F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients | |
| Rowe et al. | PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges | |
| Kanoun et al. | Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma | |
| Mohs et al. | Hand-held spectroscopic device for in vivo and intraoperative tumor detection: contrast enhancement, detection sensitivity, and tissue penetration | |
| Servagi-Vernat et al. | A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy | |
| Zangheri et al. | PET/CT and breast cancer | |
| JP6501524B2 (ja) | Ｐｓｍａ上昇により致死性前立腺癌が同定される | |
| Udovicich et al. | 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: current state and future trends | |
| Bailey et al. | Performance of 68Ga-PSMA PET/CT for prostate cancer management at initial staging and time of biochemical recurrence | |
| Delouya et al. | 18F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer | |
| Lee et al. | Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy | |
| Tang et al. | Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5, 7-Diethyl-2-(4-(2-[18F] fluoroethoxy) phenyl) pyrazolo [1, 5-a] pyrimidin-3-yl)-N, N-diethylacetamide ([18F] VUIIS1008) in glioma | |
| Basu et al. | Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment | |
| Kurihara et al. | Molecular imaging using PET for breast cancer | |
| Abgral et al. | Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual‐phase 18FDG PET‐CT imaging in patients with head and neck cancer | |
| Zhou et al. | Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer | |
| Estorch et al. | Future challenges of multimodality imaging | |
| Lewis et al. | [18f] fluoroethyltyrosine-induced cerenkov luminescence improves image-guided surgical resection of glioma | |
| Wáng et al. | Molecular imaging: from bench to clinic | |
| Zhao et al. | Somatostatin receptor imaging with [68Ga] Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma | |
| Bouchelouche et al. | Advances in imaging modalities in prostate cancer | |
| Luo et al. | Harnessing the power of molecular imaging for drug discovery and development | |
| Conti | New prospects for PET in prostate cancer imaging: a physicist's viewpoint | |
| Netzer et al. | To operate or to radiate: the added value of the maximal standardized uptake value in PET–FDG in cervical cancer patients |